When beginning any assay development program, you must consider a number of factors before you are on the road to a finished product. Between reagent selections, regulatory requirements, controls, sample collection, cassette design, and end user requirements, details can slip through the cracks. Even the smallest missed detail can halt progress and delay your development timeline.
DCN Dx, a Carlsbad, California-based developer and manufacturer of rapid point-of-care diagnostic tests, today entered into a distribution agreement with nanoComposix, a San Diego, California-based manufacturer of precisely engineered and highly characterized nanoparticles.
Should you select monoclonal or polyclonal antibodies for your lateral flow rapid test? Some readers are probably wondering why polyclonal antibodies are not a thing of the past, like manual transmissions on cars and telephone landlines. However, the older models still have many advantages. This blog explores these advantages in the context of lateral flow assays.